GlassScriptPhysician profile
Marion L Sennett
NPI 1962498295
$4,012.97
in general payments reported to CMS, 2019-2025
37 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $314 · 2021: $1,275 · 2022: $755 · 2023: $477 · 2024: $494 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $618.99 | 2019-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $545.90 | 2021-2025 | |
| Abbvie INC. | $372.27 | 2021-2022 | |
| Dexcom, INC. | $220.78 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $213.91 | 2019-2024 | Mounjaro |
| Vanda Pharmaceuticals INC. | $197.09 | 2021-2023 | Hetlioz |
| Astrazeneca Pharmaceuticals LP | $195.61 | 2019-2025 | Farxiga, Airsupra |
| Corcept Therapeutics | $169.28 | 2021-2023 | Korlym |
| Janssen Scientific Affairs, LLC | $124.95 | 2022 | |
| Amarin Pharma, INC. | $119.47 | 2019-2021 | |
| Esperion Therapeutics, INC. | $118.37 | 2020-2023 | Nexletol |
| Glaxosmithkline, LLC. | $106.37 | 2023-2024 | Trelegy Ellipta, Shingrix |
| Xeris Pharmaceuticals, INC. | $97.32 | 2021-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.42 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $75.57 | 2022-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $65.52 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $65.49 | 2023-2025 | Rexulti |
| Abbott Laboratories | $62.68 | 2021-2022 | |
| Pfizer INC. | $59.81 | 2021-2024 | |
| Mannkind Corporation | $58.24 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $55.74 | 2020-2025 | Zoryve |
| Amgen INC. | $55.15 | 2019-2022 | |
| Azurity Pharmaceuticals, INC. | $41.91 | 2023 | Horizant |
| Sanofi Pasteur INC. | $36.23 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $30.08 | 2021-2022 | |
| Allergan, INC. | $29.50 | 2020 | |
| Insulet Corporation | $22.04 | 2025 | Omnipod |
| Paratek Pharmaceuticals, INC. | $21.41 | 2022 | |
| Nestle Healthcare Nutrition INC. | $20.22 | 2021 | |
| Eisai INC. | $19.07 | 2021 | |
| Mylan Specialty L.P. | $18.06 | 2024 | Yupelri |
| Beta Bionics, INC. | $16.44 | 2024 | Ilet Bionic Pancreas |
| Shield Therapeutics INC | $16.11 | 2023 | Accrufer |
| Clarus Therapeutics INC. | $15.12 | 2021 | |
| Hikma Pharmaceuticals USA | $13.38 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.62 | 2019 | |
| Merck Sharp & Dohme LLC | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Sennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.